A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 7, 2008, Pages 924-931

  Fantin, S ^a   Maspero, J ^b   Bisbal, C ^c   Agache, I ^d   Donado, E ^e   Borja, J ^e   Mola, O ^e   Izquierdo, I ^e  

^a Presidente Perón Hospital   (Argentina)

^b Unidad de Investigación   (Argentina)

^c Hospital Regional Rancagua   (Chile)

^d SC Radoi Mariana SRL Brasov ^*  (Romania)

^e J Uriach y Compania   (Spain)

Author keywords

H1 receptor antagonist; Persistent allergic rhinitis; Platelet activating factor receptor antagonist; Rupatadine

Indexed keywords

CETIRIZINE; PLACEBO; RUPATADINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NASOPHARINGITIS; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PERENNIAL RHINITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 45149093862     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01668.x     Document Type: Article

References (23)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (5 Suppl S147 S334
2. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB et al. XPERT Study group. Levocetirizine improves quality-of-life and reduces costs in long term treatment of persistent allergic rhinitis. J Allergy Clin Inmunol 2004 114 : 838 844.
3. Ciebiada M, Gorska-Ciebiada M, DuBuske L, Gorski P. Montelukast with desloratadide or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Inmunol 2006 97 : 664 671.
4. Keam SJ, Plosker GL. Rupatadine: A review of its use in the management of allergic disorders. Drugs 2007 67 : 457 474.
5. Juhlin L, Rihoux JP. Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. Acta Derm Venereol. 1990 70 : 151 153.
6. Merlos M, Giral M, Balsa D, Ferrando Q, Queralt M, Puigdement A et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997 280 : 114 121.
7. Piwinski JJ, Wong JK, Grenn MJ, Ganguly AK, Billah MM, West RE Jr et al. Dual antagonists of platelet-activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzol[5, 6] cyclohepta-[1,2-b]pyridine-11-ylidene) piperidines. J Med. Chem. 1991 34 : 457 461.
8. Presscott SM, Zimmerman GA, McIntyre TM. The production of platelet-activating factor by cultured human endothelial cells: regulation and function. In : Snyder F, editor. Platelet-activating factor and related lipid mediators. New York : Plenum Press, 1987 : 323 340.
9. Guadaño EM, Serra-Batlles J, Meseguer J, Castillo JA, De Molina M, Valero A, Picado C et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004 59 : 766 771.
10. Martinez-Cocera C, De Molina M, Marti-Guadano E, Pola J, Conde J, Borja J et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel group study. J Investig Allergol Clin Immunol 2005 15 : 22 29.
11. Saint-Martin F, Dumur JP, Perez I, Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004 14 : 34 40.
12. Stuebner P, Horak F, Zieglmayer R, Arnaiz E, Leuratti C, Pérez I et al. Effects of rupatadine versus placebo on allergen-induced symptoms in patients exposed to aeroallergens in Vienna Challenge Chamber. Ann Allergy Asth Immunol. Ann Allergy Asthma Immunol 2006 96 : 37 44.
13. Barbanoj MJ, García-Gea C, Morte A, Izquierdo I, Pérez I, Jané F. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004 50 : 311 321.
14. Barbanoj MJ, García-Gea C, Antonijoan R, Izquierdo I, Donado E, Pérez I et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp 2006 21 : 13 26.
15. Vuurman E, Theunissen E, van Leeuwen C, Jolles J. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol Clin Exp 2007 22 : 289 297.
16. Christie B. Doctors revise declaration of Helsinki. BMJ 2000 321 : 913.
17. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991 21 : 77 83.
18. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005 60 : 350 353.
19. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995 96 : 971 979.
20. ARIA At-a-glace pocket reference 2007 (1st edition). http://www.whiar. org/docs/ARIA_Glance_WM.pdf
21. Juniper E. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997 99 : S742 S749.
22. Roger A, Arnaiz E, Valero A, De la Torre F, Castillo J, Rivas P et al. Rupatadine 10 mg improves quality of live in long-term treatment of persistent allergic rhinitis abstract n°761). The XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, 10-14 June, 2006.
23. Valero A, Rivas P, Castillo J, Borja J, Donado E, Arnaiz E et al. One year safety of rupatadine 10 mg in patients with allergic rhinitis abstract no 759). The XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, 10-14 June, 2006.